CL2008001745A1 - Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer. - Google Patents
Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer.Info
- Publication number
- CL2008001745A1 CL2008001745A1 CL2008001745A CL2008001745A CL2008001745A1 CL 2008001745 A1 CL2008001745 A1 CL 2008001745A1 CL 2008001745 A CL2008001745 A CL 2008001745A CL 2008001745 A CL2008001745 A CL 2008001745A CL 2008001745 A1 CL2008001745 A1 CL 2008001745A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- imidazo
- pyrazine
- pharmaceutical composition
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso en el tratamiento del cáncer.Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use in cancer treatment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94399907P | 2007-06-14 | 2007-06-14 | |
US98793207P | 2007-11-14 | 2007-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001745A1 true CL2008001745A1 (en) | 2008-12-05 |
Family
ID=40002934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001745A CL2008001745A1 (en) | 2007-06-14 | 2008-06-12 | Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2170892A2 (en) |
JP (1) | JP2010529195A (en) |
CN (1) | CN101772500A (en) |
AR (1) | AR066958A1 (en) |
CA (1) | CA2690557A1 (en) |
CL (1) | CL2008001745A1 (en) |
MX (1) | MX2009013729A (en) |
PE (1) | PE20090365A1 (en) |
TW (1) | TW200911811A (en) |
WO (1) | WO2008156614A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120034613A (en) | 2009-04-16 | 2012-04-12 | 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) | Imidazopyrazines for use as kinase inhibitors |
TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
AU2010311511B2 (en) | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
AR080754A1 (en) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS |
ES2555261T3 (en) * | 2010-06-01 | 2015-12-30 | Bayer Intellectual Property Gmbh | Imidazopyrazines substituted |
US20130288250A1 (en) * | 2010-10-20 | 2013-10-31 | Universite Bordeaux Segalen | Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastrointestinal stromal tumors |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
CA2821834A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
WO2012162365A1 (en) | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
JP6115962B2 (en) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline derivatives |
JP6426603B2 (en) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ.ベー. | A PDE2 inhibitor such as a 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] -quinoxaline compound and a PDE10 inhibitor for use in the treatment of a neurological or metabolic disorder combination |
ES2607184T3 (en) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Phosphodiesterase 10 enzyme inhibitors |
ES2672797T3 (en) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
RS59534B1 (en) | 2014-02-13 | 2019-12-31 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
MX2017012699A (en) | 2015-04-03 | 2018-02-09 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors. |
MA42606A (en) | 2015-08-12 | 2018-06-20 | Incyte Corp | SALTS OF LSD1 INHIBITOR |
CN109414410B (en) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Formulations of LSD1inhibitors |
JP2020502070A (en) | 2016-11-30 | 2020-01-23 | ケース ウエスタン リザーブ ユニバーシティ | Combinations of 15-PGDH inhibitors with corticosteroids and / or TNF inhibitors and uses thereof |
US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
KR102633530B1 (en) * | 2017-03-31 | 2024-02-02 | 오리진 온콜로지 리미티드 | Compounds and compositions for treating blood disorders |
CN107954977A (en) * | 2017-12-15 | 2018-04-24 | 上海鼎雅药物化学科技有限公司 | The synthetic method of Raltitrexed intermediate |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CN115702156A (en) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | Pyridine amide compound |
WO2023169438A1 (en) * | 2022-03-07 | 2023-09-14 | 上海凌达生物医药有限公司 | Nitrogen-containing heterocyclic cell cycle inhibitor compounds as well as preparation method therefor and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
NZ563374A (en) * | 2002-09-23 | 2009-06-26 | Schering Corp | Imidazopyrazines as cyclin dependent kinase inhibitors |
MX2007005643A (en) * | 2004-11-10 | 2008-03-13 | Cgi Pharmaceuticals Inc | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity. |
WO2007058942A2 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
-
2008
- 2008-06-11 AR ARP080102481A patent/AR066958A1/en not_active Application Discontinuation
- 2008-06-11 MX MX2009013729A patent/MX2009013729A/en not_active Application Discontinuation
- 2008-06-11 CN CN200880101960A patent/CN101772500A/en active Pending
- 2008-06-11 WO PCT/US2008/007295 patent/WO2008156614A2/en active Application Filing
- 2008-06-11 CA CA2690557A patent/CA2690557A1/en not_active Abandoned
- 2008-06-11 PE PE2008001001A patent/PE20090365A1/en not_active Application Discontinuation
- 2008-06-11 JP JP2010512177A patent/JP2010529195A/en not_active Withdrawn
- 2008-06-11 EP EP08768351A patent/EP2170892A2/en not_active Withdrawn
- 2008-06-12 TW TW097121942A patent/TW200911811A/en unknown
- 2008-06-12 CL CL2008001745A patent/CL2008001745A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009013729A (en) | 2010-01-25 |
PE20090365A1 (en) | 2009-04-04 |
WO2008156614A2 (en) | 2008-12-24 |
CN101772500A (en) | 2010-07-07 |
AR066958A1 (en) | 2009-09-23 |
CA2690557A1 (en) | 2008-12-24 |
WO2008156614A3 (en) | 2009-02-12 |
EP2170892A2 (en) | 2010-04-07 |
TW200911811A (en) | 2009-03-16 |
JP2010529195A (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001745A1 (en) | Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer. | |
CL2008001540A1 (en) | Compounds derived from pyrrolopyridines and pyrazolopyridines; pharmaceutical composition; and use in the treatment of cancer. | |
CL2019000941A1 (en) | Substituted pyrazolo [1,5-a] pyridine compounds as ret kinase inhibitors. | |
CL2011000116A1 (en) | Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer. | |
CL2007002062A1 (en) | Compounds derived from [1,2,4] triazolo [4,3-a] pyridine, kinase inhibitors; pharmaceutical composition; and its use in the treatment of cancer. | |
CL2008002097A1 (en) | Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer. | |
CL2012000163A1 (en) | Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others. | |
CL2008003846A1 (en) | Use of compounds derived from 1,2,4-triazolo fused with heterocycles, which act as ligands of the androgen receptor (ar); compounds; Preparation process; Pharmaceutical composition and the use of said compounds for the treatment of prostate cancer. | |
CL2009001160A1 (en) | Compounds derived from fused nitrogen heterocycles and their pharmaceutical composition. | |
CL2011000489A1 (en) | Compounds derived from pyrimido [5,4-d] pyrimidine, which act as tyrosine kinase inhibitors; and pharmaceutical compositions that comprise them, useful in the treatment of diseases characterized by excessive or abnormal cell proliferation | |
CL2011000119A1 (en) | Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer. | |
ECSP088425A (en) | ACTIVITY INHIBITORS Akt | |
CL2011002956A1 (en) | Compounds derived from pyrrolo [2,3-d] pyrimidine, inhibitors of janus kinase (jak1); pharmaceutical composition; and use for the treatment of an autoimmune disease, cancer, myeloproliferative disorder, an inflammatory disease, or organ transplant rejection. | |
CL2013002177A1 (en) | Compounds derived from 9h-purines and 7h-pyrrolo [2,3-d] -pyrimidines substituted, inhibitors of pi3k class i and / or mtor; its pharmaceutical composition; its pharmaceutical combination; and its use in the treatment or prevention of cancer or neurodegenerative disorders. | |
CL2008001633A1 (en) | Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer. | |
DOP2009000196A (en) | AKT ACTIVITY INHIBITORS | |
CL2009000405A1 (en) | Compounds derived from pyrrolo [2,3 b] pyrazine, inhibitors jak and cyk; and its uses in the treatment of inflammatory diseases, autoimmune and cancer. | |
CL2008001373A1 (en) | Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer. | |
CL2013002063A1 (en) | Compounds derived from pyrrolo (pyridine, pyrimidine or pyrazine), serine / trionin kinase inhibitors; pharmaceutical composition that includes them; and its use in the treatment of cancer, inflammatory infections and autoimmune diseases. | |
CL2011001863A1 (en) | Compounds derived from phenylaminopyrimidines, anaplastic lymphoma kinase inhibitors; pharmaceutical composition; pharmacological combination; and its use in the treatment of proliferative disorders such as lymphoma, osteosarcoma, melanoma or breast, renal and prostate tumor, among others (divisional application 3552-07). | |
CL2009001274A1 (en) | Substituted triazine-derived compounds, mediated by inhibition of p13 and mtor kinase; pharmaceutical composition; preparation procedure; and its use in the treatment of different types of cancer. | |
UY31673A1 (en) | "UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211" | |
CL2009001212A1 (en) | Compounds derived from pyrrolo [2,3-d] pyrimidine, kinase inhibitors; pharmaceutical composition comprising them; and its use in the treatment of vascular dementia, CNS disorder, cancer, among others. | |
CL2013000018A1 (en) | Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others. | |
CL2008002139A1 (en) | Dimer compounds derived from pyrrolo [2,1c] [1,4] benzodiazepine-5 -one (tomaimycin), a conjugate comprising them; procedure of preparation of conjugates; pharmaceutical composition comprising the compounds or conjugates; and use of compounds and conjugates in the treatment of cancer. |